Gastric Inhibitory Polypeptide Receptor (GIPR) Antibody
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Gastric Inhibitory Polypeptide Receptor (GIPR) Antibody is a Recombinant Mouse Monoclonal antibody for the detection of Mouse、Rat Gipr.
Documents del producto
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Gastric Inhibitory Polypeptide Receptor (GIPR) |
| Host | Mouse |
| Reactivity | Mouse, Rat |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG2a |
| Expression | Recombinant |
| Purification | Purified by affinity chromatography. |
| Size 1 | 50 µl |
| Size 2 | 100 µl |
| Form | Liquid |
| Tested Applications | ELISA |
| Buffer | 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q0P543 |
| Gene ID | 381853 |
| Alias | PGQTL2,Gippr,GIP-R |
| Background | Antibody anti-GIPR |
| Status | RUO |
Descripción
GIPR is a G-protein-coupled receptor expressed primarily on pancreatic β-cells, adipose tissue, intestinal cells, and the central nervous system, where it mediates the physiological actions of GIP Upon GIP binding, GIPR activates intracellular pathways including cAMP signaling, protein kinase A, and Epac2, leading to enhanced glucose-dependent insulin secretion from β-cells GIPR also regulates lipid metabolism in adipose tissue by increasing lipogenesis and triglyceride storage through lipoprotein lipase activation GIPR signaling in bone tissue promotes osteoblast activity and bone mineralization, supporting skeletal growth and homeostasis In the central nervous system, GIPR modulates energy balance and appetite through hypothalamic pathways Genetic variations in GIPR are linked to obesity, insulin resistance, and impaired glucose metabolism due to altered GIP signaling Pharmacological therapies targeting GIPR, including GIPR agonists and dual GIP/GLP-1 receptor agonists, are being developed to improve glucose control, reduce body weight, and treat components of metabolic syndrome
Related Products
Recombinant Human GIPR N-ECD
Ver Producto
Gastric Inhibitory Polypeptide Receptor (GIPR) Antibody
Rabbit polyclonal antibody against GIPR protein. Immunogen region is Internal.
Ver Producto
Gastric Inhibitory Polypeptide Receptor (GIPR) Antibody
GIPR also called glucose-dependent insulinotropic polypeptide, is a 42-amino acid polypeptide synthesized by K cells of the duodenum and small intestine. This protein was originally identified as an activity in gut extracts that inhibited gastric acid secretion and gastrin release, but subsequently was demonstrated to stimulate insulin release potently in the presence of elevated glucose. The insulinotropic effect on pancreatic islet beta-cells was then recognized to be the principal physiologic action of GIP. Together with glucagon-like peptide-1, GIP is largely responsible for the secretion of insulin after eating. The protein is involved in several other facets of the anabolic response.
Ver Producto